Skip to Content
Søg Menu

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

/ BestPractice Nordic
ESMO22HER2Brystcancer

A major threat to human health

/ BestPractice Nordic
ESMO22Cancer

PARP inhibitors are showing promising results in treating ovarian cancer 

/ BestPractice Nordic
ESMO22Gynækologisk cancer

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

/ BestPractice Nordic
ESMO22Nyrecancer

EADV 2022 update on biologics and JAK-inhibitors for the treatment of atopic dermatitis  

/ BestPractice Nordic
EADV22Atopisk dermatitisBiologisk behandlingNyt om lægemidlerJAK-hæmmere

ESMO 2022 –” Understanding the disease to provide better care for cancer patients”  

/ BestPractice Nordic
ESMO22

Vitamin D has a protective role in the overall survival of melanoma patients 

/ BestPractice Nordic
EADV22VitaminerMelanom

Skin immune biomarker predicts the development of AD in the pediatric population 

/ BestPractice Nordic
EADV22BørnAtopisk dermatitis

Multipel sklerose (MS) og Epstein-Barr virus (EBV) – nye data underbygger en kausal sammenhæng

/ Per Brøndsted Höllsberg
MS

Alopecia areata: Better understanding opens new therapeutic approaches 

/ BestPractice Nordic
EADV22Genital WartsAtopisk dermatitisPsoriasis
Back to top